Literature DB >> 474592

Cardiac abnormalities in myotonic dystrophy. Electrophysiologic and histopathologic studies.

J Motta, C Guilleminault, M Billingham, W Barry, J Mason.   

Abstract

Eight young adult male patients with myotonic dystrophy, mean age 26 years, underwent 24-hour Holter electrocardiographic monitoring and intracardiac electrophysiologic study. Right ventricular endomyocardial biopsies were performed at the end of the electrophysiologic study in five of them. The atrial to His[A-H] interval was 155 msec in one case and less than or equal to 55 msec in all patients. Twenty-four hour Holter electrocardiographic monitoring demonstrated more than 4 premature ventricular contractions per minute in two patients and marked cyclical sinus arrhythmia during sleep in two others. Electron microscopic analysis of the endomyocardial biopsy specimens disclosed no prominent sarcoplasmic reticulum abnormalities but prominent I bands compared to previously obtained controls. Myofibrillar degeneration was seen in all cases and was associated with abnormal mitochondria in two. Cardiac abnormalities can be detected very early in the evolution of myotonic dystrophy, even prior to the onset of cardiac symptoms. The reported abnormalities appear closely related to the pathologic process affecting other skeletal muscles.

Entities:  

Mesh:

Year:  1979        PMID: 474592     DOI: 10.1016/0002-9343(79)90795-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  18 in total

1.  Cardiac involvement in patients with myotonic dystrophy, Becker's muscular dystrophy and mitochondrial myopathy.

Authors:  J Finsterer; C Stöllberger; H Keller; J Slany; B Mamoli
Journal:  Herz       Date:  1997-04       Impact factor: 1.443

Review 2.  Electrocardiographic abnormalities in patients with myotonic dystrophy.

Authors:  R C Florek; D W Triffon; D E Mann; S P Ringel; M J Reiter
Journal:  West J Med       Date:  1990-07

3.  Myotonia dystrophica--first presentation as severe left ventricular failure complicating dilated cardiomyopathy.

Authors:  L D Premawardhana; G Thirunavakarasu
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

Review 4.  Therapeutics development in myotonic dystrophy type 1.

Authors:  Erin Pennock Foff; Mani S Mahadevan
Journal:  Muscle Nerve       Date:  2011-05-23       Impact factor: 3.217

5.  QRS prolongation in myotonic muscular dystrophy and diffuse fibrosis on cardiac magnetic resonance.

Authors:  Saman Nazarian; David A Bluemke; Kathryn R Wagner; Menekhem M Zviman; Evrim Turkbey; Brian S Caffo; Monda Shehata; David Edwards; Barbara Butcher; Hugh Calkins; Ronald D Berger; Henry R Halperin; Gordon F Tomaselli
Journal:  Magn Reson Med       Date:  2010-07       Impact factor: 4.668

6.  Primary amyloidosis in a patient with myotonic dystrophy.

Authors:  I G Mackay; D Thomson; A Doig
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-04       Impact factor: 10.154

7.  Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.

Authors:  Ramesh S Yadava; Qing Yu; Mahua Mandal; Frank Rigo; C Frank Bennett; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2020-06-03       Impact factor: 6.150

8.  Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1.

Authors:  Misha Koshelev; Satyam Sarma; Roger E Price; Xander H T Wehrens; Thomas A Cooper
Journal:  Hum Mol Genet       Date:  2010-01-05       Impact factor: 6.150

9.  Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.

Authors:  Guey-Shin Wang; Debra L Kearney; Mariella De Biasi; George Taffet; Thomas A Cooper
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 10.  Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.

Authors:  Samantha LoRusso; Benjamin Weiner; W David Arnold
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.